A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2002
12/26/2002	US20020197270 Immunogenic compositions for induction of anti-tumor immunity
12/26/2002	US20020197269 Pharmaceutical composition for immunomodulation and preparation of vaccines
12/26/2002	US20020197266 Immunotherapy using interleukin 13 receptor subunit alpha 2
12/26/2002	US20020197256 Combination therapy
12/26/2002	US20020197255 Therapeutic application of chimeric and radiolabelled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
12/26/2002	US20020197245 Antitumour compositions containing taxane derivatives
12/26/2002	US20020197235 Method for short-term and long-term drug dosimetry
12/26/2002	US20020197216 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against UVB rays
12/26/2002	US20020197210 Stabilized therapeutic and imaging agents
12/26/2002	US20020197208 Low density radionuclide-containing particulate material
12/26/2002	US20020197207 Radionuclide-coated particulate material
12/26/2002	CA2391568A1 Collapsin response mediator protein-1
12/25/2002	CN1387575A Method for transfer of molecular substances with prokaryontic nucleic acid-binding proteins
12/25/2002	CN1387571A Mammalian cytokines, related reagents and methods
12/25/2002	CN1387569A Apoptin-associating protein
12/25/2002	CN1387539A Human monoclonal antibodies to prostate specific membrane antigen
12/25/2002	CN1387538A Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders
12/25/2002	CN1387531A Pyrazolo [4,3-d] pyrimidine derivs.
12/25/2002	CN1387528A Heterocyclic substd, pyrazolones
12/25/2002	CN1387527A Qinazoline derivs. as VEGF inhibitors
12/25/2002	CN1387514A Aromatic sulfone hydroxamic acid metalloprotease inhibitor
12/25/2002	CN1387444A Method of treatment using anti-ErbB antibody-maytansinoid conjugates
12/25/2002	CN1387443A 联合疫苗组合物 Combined vaccine composition
12/25/2002	CN1387438A 联合化学疗法 Combined chemotherapy
12/25/2002	CN1387437A 治疗用途 Therapeutic use
12/25/2002	CN1387433A Method for administering phosphodiesterase 4 inhibitor
12/25/2002	CN1386858A 3 novel humanized tumor cell reproduction and tumor transfer suppressor genes
12/25/2002	CN1386750A Process for preparing platelet factor 4 as genetically engineered medicine
12/25/2002	CN1386540A Medicine for treating mastropathy by exteriorly applying to acupoints
12/25/2002	CN1386537A Oral liquid of hare's-lettuce
12/25/2002	CN1386524A Chinese medicine composition for treating cancer
12/25/2002	CN1386520A Chinese medicine composition for treating acute mastitis, mastroplasia and hysteromyoma
12/25/2002	CN1097056C Counterpart of camptothecin, their application as medicine and pharmaceutical compositions contg. them
12/25/2002	CN1097055C Taxena derivs., preparation thereof formulation contg. them
12/25/2002	CN1097051C N-heteroaryl-pyridinesulfonamide derivs. and their use as endotheliin antagonists
12/25/2002	CN1096868C Medical paste for treating cancer
12/24/2002	US6498945 Free radical generation of water soluble polymer to enhance cytopathogenic efficacy
12/24/2002	US6498257 2,3-olefinic epothilone derivatives
12/24/2002	US6498252 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing these compounds
12/24/2002	US6498243 Epimorphin antagonist and process for producing it
12/24/2002	US6498233 Nucleic acid transfer system
12/24/2002	US6498195 For prophylaxis and therpy of cancer
12/24/2002	US6498181 Enhancing humoral immune response in combination with cancer therapy including surgery, radiation and immunotherapy
12/24/2002	US6498178 Inhibitors of IMPDH enzyme
12/24/2002	US6498154 Cyclic regimens using quinazolinone and benzoxazine derivatives
12/24/2002	US6498151 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors
12/24/2002	US6498150 Low molecular weight cell, bone marrow and immune stimulants
12/24/2002	US6498149 Culturing human placental decidua derived cells with surface markers as positive cd57 and bright hla.dr; 1-dehydroxy-2-(1-guanine, 1-uracil or 1-(7-ketopurine))ribofuranose deri-vatives; reduced side effects
12/24/2002	US6497906 Anticholesterol, reduced menstrual bleeding
12/24/2002	US6497904 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
12/24/2002	US6497879 Composition which comprises isolated mage-10 tumor rejection antigen precursor which is encoded by nucleic acid having specified nucleotide sequence
12/24/2002	US6497873 Rhabdovirus comprising heterologous fusion protein which facilitates fusion of rhabdovirus to target cell membrane, heterologous g stem polypeptide, rhabdovirus n, p and l proteins, deletion of nucleotide sequence encoding g protein
12/24/2002	US6497871 Polypeptide having anti-viral and anti-proliferative activity
12/24/2002	CA2172955C Liposomal defensins
12/24/2002	CA2147863C Determination of peptide motifs on mhc molecules
12/24/2002	CA2086264C Surface complexed lymphotoxin
12/24/2002	CA2075878C Cyclic peptides and use thereof
12/19/2002	WO2002101357A2 Molecular signatures of commonly fatal carcinomas
12/19/2002	WO2002101049A2 Interleukin-18 mutants, their production and use
12/19/2002	WO2002101048A2 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
12/19/2002	WO2002101046A1 Monoclonal antibody binding to mt4-mmp catalytic domain
12/19/2002	WO2002101009A2 Structural and cytoskeleton-associated proteins
12/19/2002	WO2002101008A2 Intracellular signaling molecules
12/19/2002	WO2002101005A2 A g-protein coupled receptor and uses therefor
12/19/2002	WO2002100901A2 Determination of bone-sialoprotein in bodily fluids for oncological problems
12/19/2002	WO2002100899A2 Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
12/19/2002	WO2002100897A2 Brca1/acc alpha molecular complexes, diagnostic and therapeutic applications
12/19/2002	WO2002100889A1 Novel epitope of human papilloma virus e7 antigen and cd4-positive t cells activated by the epitope
12/19/2002	WO2002100888A1 Somatostatin-dopamine chimeric analogs
12/19/2002	WO2002100858A2 Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
12/19/2002	WO2002100857A1 Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
12/19/2002	WO2002100854A1 Lactone formulations and method of use
12/19/2002	WO2002100849A2 Novel nitriles useful as reversible inhibitors of cysteine proteases
12/19/2002	WO2002100835A1 Heterocyclic compounds having antitumor activity
12/19/2002	WO2002100833A1 Rho KINASE INHIBITORS
12/19/2002	WO2002100830A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002	WO2002100826A2 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002	WO2002100824A1 A novel alkaloid derivative and a pharmaceutical composition containing the same
12/19/2002	WO2002100812A1 Carboxylic acid derivative and salt thereof
12/19/2002	WO2002100456A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002	WO2002100431A1 A pharmaceutical kit comprising anti-human seminal plasma protein single chain antibody/human carboxypeptidase fusion protein and prodrug
12/19/2002	WO2002100429A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002	WO2002100428A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002	WO2002100412A2 Stabilized dispersion of phytosterol in oil
12/19/2002	WO2002100408A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
12/19/2002	WO2002100406A1 Use of yohimbine in the preparation of immunobiologically active drugs
12/19/2002	WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002	WO2002100401A1 Soluble cdk-inhibitory indirubin derivatives
12/19/2002	WO2002100400A1 Organic nitrate-based compounds for the treatment of vasculopathies
12/19/2002	WO2002100354A2 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
12/19/2002	WO2002100353A2 Cd10-activated prodrug compounds
12/19/2002	WO2002100348A2 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	WO2002100336A2 Tissue-specific endothelial membrane proteins
12/19/2002	WO2002100332A2 Isoxazoline compounds having mif antagonist activity
12/19/2002	WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002	WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	WO2002100327A2 Substituted 1-benzazepines and derivatives thereof
12/19/2002	WO2002100325A2 Polyvalent nanoparticles
12/19/2002	WO2002087583A3 Use of hiv-protease inhibitors to block cell migration and/or invasion, tissue infiltration and oedema formation
12/19/2002	WO2002085327A3 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract

1 ... 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 ... 2211